Last $31.45 USD
Change Today +0.17 / 0.54%
Volume 459.8K
WMGI On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
NASDAQ GM
As of 5:20 PM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

wright medical group inc (WMGI) Snapshot

Open
$31.45
Previous Close
$31.28
Day High
$31.60
Day Low
$31.22
52 Week High
02/24/14 - $33.80
52 Week Low
08/30/13 - $23.70
Market Cap
1.6B
Average Volume 10 Days
421.3K
EPS TTM
$-3.10
Shares Outstanding
49.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for WRIGHT MEDICAL GROUP INC (WMGI)

wright medical group inc (WMGI) Related Bloomberg News

View More Bloomberg News

wright medical group inc (WMGI) Related Businessweek News

No Related Businessweek News Found

wright medical group inc (WMGI) Details

Wright Medical Group, Inc., a specialty orthopaedic company, provides extremity and biologic solutions that enable clinicians to alleviate pain and restore their patients’ lifestyles. The company offers products that are used primarily in foot and ankle repair, upper extremity products, and biologics products. Its extremity hardware products comprise implants and other devices to replace or reconstruct injured or diseased joints and bones of the foot, ankle, hand, wrist, fingers, toes, elbow, and shoulder. The company also provides biologic products, which are used to replace damaged or disease bone, stimulate bone growth, and provide other biological solutions for surgeons and their patients, as well as offers a bone graft product incorporating antibiotic delivery. Its biological products focus on supporting biological musculoskeletal repair by utilizing synthetic and human tissue-based materials. The company sells its products through a network of employee sales representatives, independent sales representatives, and stocking distributors in approximately 60 countries primarily in the United States, Europe, Asia, Canada, Australia, and Latin America. The company was founded in 1950 and is headquartered in Memphis, Tennessee.

898 Employees
Last Reported Date: 02/27/14
Founded in 1950

wright medical group inc (WMGI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $750.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $340.0K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $500.0K
President of International
Total Annual Compensation: $564.0K
President of Extremities - Biologics
Total Annual Compensation: $340.0K
Compensation as of Fiscal Year 2013.

wright medical group inc (WMGI) Key Developments

Wright Medical Group Inc. Announces Commercial Launch of Infinity(R) Total Ankle System

Wright Medical Group Inc. announced the full U.S. commercial launch of its Infinity(R) Total Ankle Replacement (TAR) System. The system is now available in the U.S. through Wright Medical's foot and ankle sales force. The Infinity(R) TAR System will also be available on a limited basis in select countries outside the U.S. through Wright's direct sales organization. Key features of the new Infinity(R) Total Ankle System include: Low-profile implant design -- anterior cortex sparing tibial component design. Compatibility with INBONE(R) II talar components -- provides flexibility and opportunity to address continuum of care. Seamless integration with PROPHECY(R) Pre-Operative Navigation Guides -- offers fewer surgical steps, less fluoroscopic exposure and reduced surgical time.

Wright Medical Group Inc. Reports Unaudited Consolidated Earnings Results for First Quarter Ended March 31, 2014; Revises Earnings Guidance for the Year 2014

Wright Medical Group Inc. reported unaudited consolidated earnings results for first quarter ended March 31, 2014. For the period, the company reported net sales were $71,062,000 compared to $56,293,000 in the same period last year. Operating loss was $23,046,000 compared to $13,226,000 in the same period last year. Loss from continuing operations before income taxes was $42,468,000 compared to $11,322,000 in the same period last year. Net loss from continuing operations was $30,298,000 or $0.62 per diluted share compared to $4,918,000 or $0.12 per diluted share in the same period last year. Net loss was $30,420,000 or $0.63 per diluted share compared to net income of $8,435,000 or $0.20 per diluted share in the same period last year. Operating loss, as adjusted was $14,498,000 compared to $4,434,000 in the same period last year. Net loss from continuing operations, as adjusted was $16.6 million, a decline from a net loss of $3.3 million in 2013, while diluted loss per share, as adjusted, decreased to $0.34 in the first quarter of 2014 from $0.08 in the first quarter of 2013. LBITDA was $31,904,000 against $2,325,000 for the same period a year ago. Adjusted LBITDA was $6,187,000 against adjusted EBITDA of $1,401,000 for the same period a year ago. Loss before taxes, as adjusted was $16,366,000 compared to $6,211,000 in the same period last year. Net loss, as adjusted was $16,558,000 compared to income of $3,347,000 in the same period last year. Net loss from continuing operations, as adjusted, per diluted share was $0.34 against $0.08 for the same period a year ago. Net cash used in operating activities was $27,240,000 against $5,168,000 for the same period a year ago. Capital expenditures was $7,836,000 against $3,740,000 for the same period a year ago. The company narrowed its previous guidance range of $305 million to $312 million and now anticipates net sales from continuing operations, or Extremity and Biologics revenue, for 2014 of approximately $308 million to $312 million. This represents a growth rate of 27% to 29% (including Solana, OrthoPro and Biotech acquisitions). The company reiterates its previously issued full-year 2014 adjusted EBITDA from continuing operations, as described in the GAAP to non-GAAP reconciliation provided later in this release, of negative $20.0 million to negative $15.0 million. The Company expects to exit 2014 with positive adjusted EBITDA. The company anticipates adjusted earnings per share from continuing operations, including stock-based compensation, for full-year 2014 to be in the range of $1.28 to $1.38 per diluted share, based on approximately 49.9 million shares outstanding.

Wright Medical Group Inc. to Report Q1, 2014 Results on Apr 30, 2014

Wright Medical Group Inc. announced that they will report Q1, 2014 results at 3:00 PM, Central Standard Time on Apr 30, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WMGI:US $31.45 USD +0.17

WMGI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cyberonics Inc $60.51 USD +0.88
Exactech Inc $23.05 USD +0.13
ICU Medical Inc $59.75 USD +0.68
Thoratec Corp $31.40 USD +0.07
Tornier NV $21.60 USD +0.16
View Industry Companies
 

Industry Analysis

WMGI

Industry Average

Valuation WMGI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.0x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WRIGHT MEDICAL GROUP INC, please visit www.wmt.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.